MedTrace Logo

Multimodal Pain Treatment for Breast Cancer Surgery - a Prospective Cohort Study

NCT04875559 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 236

Last updated 2023-07-14

No results posted yet for this study

Summary

Breast cancer is one of the most common types of cancer among women worldwide. (1) Breast-conserving surgery or mastectomy is indicated for the majority of patients with this type of cancer. (2) Postoperative pain is frequent in this population, with almost 50 % experiencing acute pain and 25-60 % subsequently live with chronic pain. (3-5) Today no golden standard for postoperative pain management regarding breast cancer surgeries exists, and there is definitely room for improvement. Especially considering the large population of women with breast cancer and consequences of acute and chronic pain, such as prolonged recovery and affected quality of life. (6,7) With the present study, we aim to optimise postoperative pain treatment and investigate the effect of a standardised multimodal postoperative analgesic regimen based on previous recommendations. (4,8,9)

Conditions

  • Breast Cancer Female
  • Postoperative Pain
  • Postoperative Nausea and Vomiting

Interventions

OTHER

Standardised multimodal pain treatment regimen

Preoperatively: * Paracetamol 1000 mg p.o. * Celecoxib 400 mg p.o. * Dexamethasone 12 mg p.o. Perioperatively: * Ondansetron 4 mg IV * Bupivacaine 2.5 mg/mL, 20 mL LIA * Oxycodone 0.15 mg/kg IV (Oxycodone 0.25 mg/kg for ALND) Postoperatively: * Paracetamol 1000 mg p.o. every 6h PRN * Ibuprofen 400 mg p.o. every 6h (day 1-5) PRN * Oxycodone 5 mg IV or 10 mg p.o. PRN * Ondansetron 4 mg IV or p.o. PRN

Sponsors & Collaborators

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Anne Sofie N Therkelsen, MD · Department of Anaesthesiology, Zealand University Hospital, Roskilde, Denmark

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-19
Primary Completion
2022-08-04
Completion
2022-08-18

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04875559 on ClinicalTrials.gov